Literature DB >> 29310535

Associations of osteoprotegerin with coronary artery calcification among women with systemic lupus erythematosus and healthy controls.

I G Poornima1, K Shields2, L H Kuller3, S M Manzi2, R Ramsey-Goldman4, C Richardson5, E Rhew6, D D Dunlop7, J Song8, D Edmundowicz9, G T Kondos10, J J Carr11, C B Langman12, H Price13, A H Chung4, L B Santelices2, R H Mackey14.   

Abstract

Objective We tested the hypothesis that higher circulating levels of osteoprotegerin (OPG) are related to higher levels of coronary artery calcification (CAC) among women with systemic lupus erythematosus (SLE) compared with healthy controls (HCs). Methods Among 611 women in two age- and race-matched SLE case-control studies, OPG was assayed in stored blood samples (HEARTS: plasma, n cases/controls = 122/124, and SOLVABLE: serum, n cases/controls = 185/180) and CAC was measured by electron beam computed tomography. Results In both studies, SLE patients had higher OPG and CAC levels than HCs. Higher OPG was associated with high CAC (>100 vs.100) among SLE, and with any CAC (>0 vs. 0) among HCs. Multivariable-adjusted OR (95% CI) for OPG tertile 3 vs. 1 was 3.58 (1.19, 10.76), p trend = 0.01 for SLE, and 2.28 (1.06, 4.89), p trend = 0.04 for HCs. Associations were attenuated when age-adjusted, but remained significant for HC women aged ≥ 40 and SLE women aged ≥ 50. ROC analyses identified 4.60 pmol/l as the optimal OPG cutpoint for predicting high CAC (>100) among SLE patients with sensitivity = 0.74 and specificity = 0.61, overall, but 0.92 and 0.52, respectively, for SLE patients aged ≥ 50. Conclusion Our cross-sectional results suggest that higher OPG levels are related to higher CAC levels among women with SLE vs. healthy controls.

Entities:  

Keywords:  Systemic lupus erythematosus; coronary calcification; osteoprotegerin

Year:  2018        PMID: 29310535      PMCID: PMC6026582          DOI: 10.1177/0961203317751060

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  30 in total

1.  Estimation of the Youden Index and its associated cutoff point.

Authors:  Ronen Fluss; David Faraggi; Benjamin Reiser
Journal:  Biom J       Date:  2005-08       Impact factor: 2.207

2.  Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus.

Authors:  A N Kiani; P Aukrust; T Ueland; I Hollan; E Barr; L S Magder; M Petri
Journal:  Lupus       Date:  2016-12-06       Impact factor: 2.911

3.  Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality.

Authors:  Wolfgang Lieb; Philimon Gona; Martin G Larson; Joseph M Massaro; Izabella Lipinska; John F Keaney; Jian Rong; Diane Corey; Udo Hoffmann; Caroline S Fox; Ramachandran S Vasan; Emelia J Benjamin; Christopher J O'Donnell; Sekar Kathiresan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-05-06       Impact factor: 8.311

4.  The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects.

Authors:  Dhakshinamurthy Vijay Anand; Avijit Lahiri; Eric Lim; David Hopkins; Roger Corder
Journal:  J Am Coll Cardiol       Date:  2006-04-19       Impact factor: 24.094

5.  Sex and ethnic differences in 47 candidate proteomic markers of cardiovascular disease: the Mayo Clinic proteomic markers of arteriosclerosis study.

Authors:  Charles X Kim; Kent R Bailey; George G Klee; Allison A Ellington; Guanghui Liu; Thomas H Mosley; Hamid Rehman; Iftikhar J Kullo
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

6.  Osteoprotegerin and soluble receptor activator of nuclear factor-kappaB ligand and risk for coronary events: a nested case-control approach in the prospective EPIC-Norfolk population study 1993-2003.

Authors:  Anne G Semb; Thor Ueland; Pål Aukrust; Nicholas J Wareham; Robert Luben; Lars Gullestad; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-03-26       Impact factor: 8.311

7.  Relationship between circulating serum osteoprotegerin and total receptor activator of nuclear κ-B ligand levels, triglycerides, and coronary calcification in postmenopausal women.

Authors:  Indu G Poornima; Rachel H Mackey; Alhaji M Buhari; Jane A Cauley; Karen A Matthews; Lewis H Kuller
Journal:  Menopause       Date:  2014-07       Impact factor: 2.953

8.  Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients.

Authors:  Diana Carmona-Fernandes; Maria José Santos; Inês Pedro Perpétuo; João Eurico Fonseca; Helena Canhão
Journal:  Arthritis Res Ther       Date:  2011-10-25       Impact factor: 5.156

9.  Association of Coronary Artery Calcium in Adults Aged 32 to 46 Years With Incident Coronary Heart Disease and Death.

Authors:  John Jeffrey Carr; David R Jacobs; James G Terry; Christina M Shay; Stephen Sidney; Kiang Liu; Pamela J Schreiner; Cora E Lewis; James M Shikany; Jared P Reis; David C Goff
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

10.  Distribution of alkaline phosphatase, osteopontin, RANK ligand and osteoprotegerin in calcified human carotid atheroma.

Authors:  Catherine L Higgins; Salim Isbilir; Pamela Basto; Iou Yih Chen; Muthiah Vaduganathan; Periyanan Vaduganathan; Michael J Reardon; Gerald Lawrie; Leif Peterson; Joel D Morrisett
Journal:  Protein J       Date:  2015-10       Impact factor: 2.371

View more
  1 in total

Review 1.  Serum biomarkers for arterial calcification in humans: A systematic review.

Authors:  Nienke M S Golüke; Marit A Schoffelmeer; Annemarieke De Jonghe; Mariëlle H Emmelot-Vonk; Pim A De Jong; Huiberdina L Koek
Journal:  Bone Rep       Date:  2022-06-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.